Mylan Laboratories Limited Sustainability Profile
Mylan Laboratories Limited, a prominent player in the pharmaceutical industry, is headquartered in India and operates extensively across various global markets. Founded in 1961, Mylan has established itself as a leader in generic and specialty medications, focusing on areas such as oncology, infectious diseases, and cardiovascular health. The company is renowned for its commitment to quality and accessibility, offering a diverse portfolio of over 1,000 products, including injectables and biosimilars. Mylan's innovative approach and robust manufacturing capabilities have positioned it as a trusted provider in the healthcare sector. With a strong market presence and a dedication to improving patient outcomes, Mylan Laboratories continues to achieve significant milestones, reinforcing its reputation as a key contributor to global health solutions.
DitchCarbon Score
How does Mylan Laboratories Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mylan Laboratories Limited's score of 14 is lower than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mylan Laboratories Limited's reported carbon emissions
Mylan Laboratories Limited, headquartered in India, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Mylan may not have established formal commitments to reduce its carbon footprint or may not publicly disclose such information. In the context of the pharmaceutical industry, many companies are increasingly adopting science-based targets and sustainability initiatives to address climate change. However, without specific emissions data or commitments from Mylan Laboratories Limited, it is challenging to assess their position relative to industry standards or peers.
How Carbon Intensive is Mylan Laboratories Limited's Industry?
How Carbon Intensive is Mylan Laboratories Limited's Location?
Mylan Laboratories Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mylan Laboratories Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
